Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.

Owusu BY, Thomas S, Venukadasula P, Han Z, Janetka JW, Galemmo RA Jr, Klampfer L.

Oncotarget. 2017 May 29. doi: 10.18632/oncotarget.18260. [Epub ahead of print]

2.

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.

Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ.

Nature. 2017 Jun 22;546(7659):528-532. doi: 10.1038/nature22972. Epub 2017 Jun 14.

PMID:
28614296
3.

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Mydock-McGrane LK, Hannan TJ, Janetka JW.

Expert Opin Drug Discov. 2017 Jul;12(7):711-731. doi: 10.1080/17460441.2017.1331216. Epub 2017 Jun 2. Review.

PMID:
28506090
4.

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

Owusu BY, Galemmo R, Janetka J, Klampfer L.

Cancers (Basel). 2017 Apr 17;9(4). pii: E35. doi: 10.3390/cancers9040035. Review.

5.

Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1.

Budelier MM, Cheng WWL, Bergdoll L, Chen ZW, Janetka JW, Abramson J, Krishnan K, Mydock-McGrane L, Covey DF, Whitelegge JP, Evers AS.

J Biol Chem. 2017 Jun 2;292(22):9294-9304. doi: 10.1074/jbc.M116.773069. Epub 2017 Apr 10.

PMID:
28396346
6.

Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions.

Kalas V, Pinkner JS, Hannan TJ, Hibbing ME, Dodson KW, Holehouse AS, Zhang H, Tolia NH, Gross ML, Pappu RV, Janetka J, Hultgren SJ.

Sci Adv. 2017 Feb 10;3(2):e1601944. doi: 10.1126/sciadv.1601944. eCollection 2017 Feb.

7.

Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins.

Budelier MM, Cheng WW, Bergdoll L, Chen ZW, Abramson J, Krishnan K, Qian M, Covey DF, Janetka JW, Evers AS.

Anal Chem. 2017 Feb 21;89(4):2636-2644. doi: 10.1021/acs.analchem.6b05003. Epub 2017 Feb 9.

8.

Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections.

Mydock-McGrane L, Cusumano Z, Han Z, Binkley J, Kostakioti M, Hannan T, Pinkner JS, Klein R, Kalas V, Crowley J, Rath NP, Hultgren SJ, Janetka JW.

J Med Chem. 2016 Oct 27;59(20):9390-9408. Epub 2016 Oct 14.

PMID:
27689912
9.

α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.

Han Z, Harris PK, Karmakar P, Kim T, Owusu BY, Wildman SA, Klampfer L, Janetka JW.

ChemMedChem. 2016 Mar 17;11(6):585-99. doi: 10.1002/cmdc.201500600. Epub 2016 Feb 17.

PMID:
26889658
10.

Characterization of parasite-specific indels and their proposed relevance for selective anthelminthic drug targeting.

Wang Q, Heizer E, Rosa BA, Wildman SA, Janetka JW, Mitreva M.

Infect Genet Evol. 2016 Apr;39:201-11. doi: 10.1016/j.meegid.2016.01.025. Epub 2016 Jan 30.

11.

Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.

Jarvis C, Han Z, Kalas V, Klein R, Pinkner JS, Ford B, Binkley J, Cusumano CK, Cusumano Z, Mydock-McGrane L, Hultgren SJ, Janetka JW.

ChemMedChem. 2016 Feb 17;11(4):367-73. doi: 10.1002/cmdc.201600006. Epub 2016 Jan 26.

12.

Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.

Mydock-McGrane LK, Cusumano ZT, Janetka JW.

Expert Opin Ther Pat. 2016;26(2):175-97. doi: 10.1517/13543776.2016.1131266. Epub 2016 Jan 22. Review.

PMID:
26651364
13.

Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.

Greene SE, Hibbing ME, Janetka J, Chen SL, Hultgren SJ.

MBio. 2015 Jun 30;6(4):e00820. doi: 10.1128/mBio.00820-15.

14.

Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.

Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW.

Bioorg Med Chem. 2015 May 15;23(10):2328-43. doi: 10.1016/j.bmc.2015.03.072. Epub 2015 Apr 4.

PMID:
25882520
15.

Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Han Z, Harris PK, Jones DE, Chugani R, Kim T, Agarwal M, Shen W, Wildman SA, Janetka JW.

ACS Med Chem Lett. 2014 Oct 9;5(11):1219-24. doi: 10.1021/ml500254r. eCollection 2014 Nov 13.

16.

A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131.

Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA.

J Infect Dis. 2013 Sep;208(6):921-8. doi: 10.1093/infdis/jit245. Epub 2013 Jun 3.

17.

Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.

Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4738-45. doi: 10.1128/AAC.00447-12. Epub 2012 Jun 25.

18.

Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO.

Yang B, Hird AW, Russell DJ, Fauber BP, Dakin LA, Zheng X, Su Q, Godin R, Brassil P, Devereaux E, Janetka JW.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4907-11. doi: 10.1016/j.bmcl.2012.04.104. Epub 2012 Apr 30.

PMID:
22704236
19.

Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.

Kostakioti M, Hadjifrangiskou M, Cusumano CK, Hannan TJ, Janetka JW, Hultgren SJ.

Infect Immun. 2012 Aug;80(8):2826-34. doi: 10.1128/IAI.00283-12. Epub 2012 Jun 4.

20.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

Oza V, Ashwell S, Almeida L, Brassil P, Breed J, Deng C, Gero T, Grondine M, Horn C, Ioannidis S, Liu D, Lyne P, Newcombe N, Pass M, Read J, Ready S, Rowsell S, Su M, Toader D, Vasbinder M, Yu D, Yu Y, Xue Y, Zabludoff S, Janetka J.

J Med Chem. 2012 Jun 14;55(11):5130-42. doi: 10.1021/jm300025r. Epub 2012 Jun 4.

PMID:
22551018

Supplemental Content

Loading ...
Support Center